L-Nutra Revenue and Competitors

Location

#3551

Growjo Ranking

Health

Industry

Estimated Revenue & Valuation

  • L-Nutra's estimated annual revenue is currently $16.8M per year.(i)
  • L-Nutra's estimated revenue per employee is $243,000

Employee Data

  • L-Nutra has 69 Employees.(i)
  • L-Nutra grew their employee count by 21% last year.

L-Nutra's People

NameTitleEmail/Phone
1
Chief Strategy & Business Development OfficerReveal Email/Phone
2
Chief Financial OfficerReveal Email/Phone
3
Chief Medical OfficerReveal Email/Phone
4
Chief Operating OfficerReveal Email/Phone
5
Chief Marketing OfficerReveal Email/Phone
6
Chief Operations OfficerReveal Email/Phone
7
Chief Affiliate OfficerReveal Email/Phone
8
VP Sales and Marketing, USReveal Email/Phone
9
Head DTC and HCP MarketingReveal Email/Phone
10
Head Technology and MarketingReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$14.3M599%N/AN/A
#2
$179.6M5327%N/AN/A
#3
$6.5M303%N/AN/A
#4
$5.3M28-3%N/AN/A
#5
$12.4M5128%N/AN/A
#6
$13.6M56-10%N/AN/A
#7
$6.5M30-12%N/AN/A
#8
$18M746%N/AN/A
#9
$10.2M472%N/AN/A
#10
$181.6M53813%N/AN/A
Add Company

What Is L-Nutra?

L-Nutra is the leading nutritechnology company, developing innovative Fasting Mimicking Diets (FMD) that can be consumed for a predetermined number of consecutive days, with the frequency dependent on the condition and patient. FMDs nourish the body while keeping it in a fasting mode, which promotes positive long-term effects on biological aging, health and a variety of other factors, such as weight, abdominal fat , and maintaining healthy levels of glucose, cholesterol, blood pressure, and other key health factors. L-Nutra's first generation of FMDs includes ProLon® and Chemolieve®. ProLon is a 5-day FMD aimed at promoting longevity, managing body weight, and improving health by supporting cellular protection, multi-system regeneration and rejuvenation. ProLon launched in the United States in 2016. Chemolieve is a 4-day FMD being studied for use with oncology patients to protect the normal cells of the body and decrease side effects of chemotherapy without interfering with its efficacy.

keywords:N/A

N/A

Total Funding

69

Number of Employees

$16.8M

Revenue (est)

21%

Employee Growth %

N/A

Valuation

N/A

Accelerator

L-Nutra News

2022-04-17 - L-Nutra Reports Initial Data Showing Improvements in ...

D., CEO and Chairman of L-Nutra Inc. Obesity and metabolic dysfunction have long been linked to increased prostate cancer mortality and overall...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$12.7M6944%N/A
#2
$15.3M6911%N/A
#3
$18M698%N/A
#4
$11.2M696%N/A
#5
$15.1M691%$12M